{"organizations": [], "uuid": "2017689fb9ecc74d7cd897a7c80e9eb1fb95e37c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ultragenyx-posts-positive-topline/brief-ultragenyx-posts-positive-topline-results-of-phase-1-2-clinical-study-of-investigational-gene-therapy-dtx301-idUSFWN1QP0HY", "country": "US", "domain_rank": 408, "title": "BRIEF-Ultragenyx Posts Positive Topline Results Of Phase 1/2 Clinical Study Of Investigational Gene Therapy DTX301", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.997, "site_type": "news", "published": "2018-03-07T21:20:00.000+02:00", "replies_count": 0, "uuid": "2017689fb9ecc74d7cd897a7c80e9eb1fb95e37c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ultragenyx-posts-positive-topline/brief-ultragenyx-posts-positive-topline-results-of-phase-1-2-clinical-study-of-investigational-gene-therapy-dtx301-idUSFWN1QP0HY", "ord_in_thread": 0, "title": "BRIEF-Ultragenyx Posts Positive Topline Results Of Phase 1/2 Clinical Study Of Investigational Gene Therapy DTX301", "locations": [], "entities": {"persons": [], "locations": [{"name": "ornithine transcarbamylase", "sentiment": "none"}, {"name": "ureagenesis", "sentiment": "none"}], "organizations": [{"name": "ultragenyx pharmaceutical inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - Ultragenyx Pharmaceutical Inc:\n* ULTRAGENYX ANNOUNCES POSITIVE TOPLINE RESULTS AND DMC REVIEW FROM FIRST COHORT OF PHASE 1/2 CLINICAL STUDY OF DTX301, AN INVESTIGATIONAL GENE THERAPY IN ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY\n* ULTRAGENYX PHARMACEUTICAL INC - ‍COHORT 2 PATIENT ENROLLMENT TO BEGIN IN MARCH 2018; DATA EXPECTED IN SECOND HALF OF 2018​\n* ULTRAGENYX PHARMACEUTICAL INC - ‍UREAGENESIS NORMALIZED IN ONE PATIENT AND FURTHER INCREASED BY 24 WEEKS​\n* ULTRAGENYX - ‍IN DTX301 COHORT 1, AS OF FEB 15, THERE WERE NO INFUSION-RELATED ADVERSE EVENTS & NO SERIOUS ADVERSE EVENTS REPORTED​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-07T21:20:00.000+02:00", "crawled": "2018-03-08T17:20:36.017+02:00", "highlightTitle": ""}